权威发布|特利加压素在肝硬化并发症临床应用的实践指导(2021版)

2022-09-12 消化界 消化界

目前,特利加压素已被用于食管静脉曲张破裂出血、HRS等肝硬化并发症的治疗。然而在临床实践中,对特利加压素的最佳剂量、疗程、停药时机,以及药物不良反应的监测和处理等问题仍存有争议。

肝硬化在全球死亡原因排名中居第11位,2017年全球失代偿期肝硬化患者达1060万例,代偿期肝硬化患者达1.12亿例。肝硬化患者门静脉压力增高,处于高动力循环状态,且伴有系统性炎症反应的加重,进而导致腹水、食管胃静脉曲张破裂出血、肝性脑病、肝肾综合征(HRS)等并发症的发生。

目前,特利加压素已被用于食管静脉曲张破裂出血、HRS等肝硬化并发症的治疗。然而在临床实践中,对特利加压素的最佳剂量、疗程、停药时机,以及药物不良反应的监测和处理等问题仍存有争议。

特利加压素在肝硬化并发症的临床应用指导声明

指导声明1:推荐特利加压素用于治疗肝硬化急性食管胃静脉曲张出血。

指导声明2:对于肝硬化急性消化道出血患者,若怀疑出血来源为食管胃静脉曲张破裂,则可在内镜检查前考虑使用特利加压素。

指导声明3:对于肝硬化急性消化道出血合并肾功能不全患者,可优先考虑使用特利加压素。

指导声明4:推荐特利加压素用于1型HRS的治疗。

指导声明5:对于肝硬化伴重度腹水或难治性腹水患者,若利尿剂无效或无法耐受利尿剂相关不良反应,则可考虑使用特利加压素。

指导声明6:推荐特利加压素用于预防肝硬化伴腹水患者腹腔穿刺大量(>5 L)放腹水后出现的循环功能障碍。

指导声明7:对于肝硬化伴细菌感染患者,可考虑使用特利加压素改善全身血流动力学状态、微循环和组织灌注。

指导声明8:特利加压素可降低肝切除术中和术后门静脉压力,且有助于减少术中失血量和输血需求。

指导声明9:特利加压素可用于改善肝移植术后全身血流动力学状态和肾功能。

指导声明10:特利加压素引起的不良反应主要包括胃肠道反应、电解质紊乱、心血管系统和呼吸系统不良事件等,常可通过药物减量、停药或对症治疗后好转。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1835939, encodeId=c2131835939e4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Dec 19 14:44:14 CST 2022, time=2022-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736857, encodeId=f1761e368579e, content=<a href='/topic/show?id=224b6e85219' target=_blank style='color:#2F92EE;'>#特利加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67852, encryptionId=224b6e85219, topicName=特利加压素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cfa34187329, createdName=sunrural_42825368, createdTime=Fri Jan 20 03:44:14 CST 2023, time=2023-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992066, encodeId=66651992066bb, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Aug 04 04:44:14 CST 2023, time=2023-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758472, encodeId=9cca1e5847267, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun May 21 13:44:14 CST 2023, time=2023-05-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1835939, encodeId=c2131835939e4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Dec 19 14:44:14 CST 2022, time=2022-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736857, encodeId=f1761e368579e, content=<a href='/topic/show?id=224b6e85219' target=_blank style='color:#2F92EE;'>#特利加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67852, encryptionId=224b6e85219, topicName=特利加压素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cfa34187329, createdName=sunrural_42825368, createdTime=Fri Jan 20 03:44:14 CST 2023, time=2023-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992066, encodeId=66651992066bb, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Aug 04 04:44:14 CST 2023, time=2023-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758472, encodeId=9cca1e5847267, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun May 21 13:44:14 CST 2023, time=2023-05-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1835939, encodeId=c2131835939e4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Dec 19 14:44:14 CST 2022, time=2022-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736857, encodeId=f1761e368579e, content=<a href='/topic/show?id=224b6e85219' target=_blank style='color:#2F92EE;'>#特利加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67852, encryptionId=224b6e85219, topicName=特利加压素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cfa34187329, createdName=sunrural_42825368, createdTime=Fri Jan 20 03:44:14 CST 2023, time=2023-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992066, encodeId=66651992066bb, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Aug 04 04:44:14 CST 2023, time=2023-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758472, encodeId=9cca1e5847267, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun May 21 13:44:14 CST 2023, time=2023-05-21, status=1, ipAttribution=)]
    2023-08-04 fyxzlh
  4. [GetPortalCommentsPageByObjectIdResponse(id=1835939, encodeId=c2131835939e4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Mon Dec 19 14:44:14 CST 2022, time=2022-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736857, encodeId=f1761e368579e, content=<a href='/topic/show?id=224b6e85219' target=_blank style='color:#2F92EE;'>#特利加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67852, encryptionId=224b6e85219, topicName=特利加压素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cfa34187329, createdName=sunrural_42825368, createdTime=Fri Jan 20 03:44:14 CST 2023, time=2023-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992066, encodeId=66651992066bb, content=<a href='/topic/show?id=11b13296e8e' target=_blank style='color:#2F92EE;'>#加压素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32967, encryptionId=11b13296e8e, topicName=加压素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Fri Aug 04 04:44:14 CST 2023, time=2023-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758472, encodeId=9cca1e5847267, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sun May 21 13:44:14 CST 2023, time=2023-05-21, status=1, ipAttribution=)]
    2023-05-21 丁鹏鹏

相关资讯

Intens Care Med:脓毒性休克患者输注特利加压素与去甲肾上腺素的疗效比较!

由此可见,在这项多中心,随机,双盲试验中,研究人员观察到脓毒性休克患者特利加压素和NE输注之间的死亡率没有差异。特利加压素组患者的严重不良事件发生率较高。

NEJM:特利加压素联合白蛋白治疗1型肝肾综合征

对于肝硬化且伴有1型肝肾综合征的患者,在白蛋白治疗基础上,使用特利加压素可改善患者肾功能,但导致呼吸衰竭等严重不良事件风险增加。

Hepatology:特利加压素可较去甲肾上腺素给予更好的改善ACLF患者的生存率

肝肾综合征(HRS)是肝硬化和急慢性肝衰竭(ACLF)短期较高死亡率的主要病因。特利加压素和去甲肾上腺素常规用于治疗肝硬化伴有HRS的患者,并被发现同样有效。但是,目前尚无数据比较特利加压素与去甲肾上

Mallinckrodt的特利加压素达到1型肝肾综合症III期研究的主要目标

Mallinckrodt宣布其特利加压素治疗1型肝肾综合症(HRS-1)成人患者的III期CONFIRM试验符合其主要终点和几乎所有预先指定的次要目标。这一消息促使股票周四上涨11%,该公司计划于明年初向FDA提交营销申请用于治疗。特利加压素是一种对V1受体具有选择性的加压素类似物。

特利加压素治疗1型肝肾综合症:获得FDA咨询委员会的投票支持

如果不进行治疗,HRS-1的中位生存时间约为两周,三个月内的死亡率超过80%。

临床重症:特利加压素?去甲肾上腺素?亦或都用在脓毒性休克中?

当静脉液体复苏不能使平均动脉压(MAP)维持在65mmHg以上时,血管升压药治疗便成为脓毒性休克管理策略中的重要基石之一 。去甲肾上腺素是推荐的首选血管升压药,但低反应性是一个重要的临床问题,有时需要高剂量才能达到目标MAP。如此高剂量的儿茶酚胺治疗可能增加致死性心律失常、免疫抑制和死亡的风险。